Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. Carboplatin possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Carboplatin is used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
DMSO can inactivate Carboplatin's activity
Int J Mol Sci. 2022 Jun 3;23(11):6290.
Carboplatin-Induced Thrombocytopenia through JAK2 Downregulation, S-Phase Cell Cycle Arrest, and Apoptosis in Megakaryocytes
Carboplatin purchased from AbMole
Universitat Freiburg im Breisgau. 2020 Jul.
Investigation of chemotherapy-induced non-coding RNA expression alterations in clinical breast cancer management
Carboplatin purchased from AbMole
Int J Oncol. 2020 Jan;56(1):47-68.
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Carboplatin purchased from AbMole
Cell Cycle. 2018;17(10):1235-1244.
Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Carboplatin purchased from AbMole
Cell Death Dis. 2018 Feb 12;9(2):213.
Autophagy mediates glucose starvationinduced glioblastoma cell quiescence and chemoresistance through coordinating cell metabolism, cell cycle, and survival
Carboplatin purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | 5637 cells |
Preparation method | Cells were dosed and incubated with 290 μM carboplatin or 290 μM carboplatin combined with 0.08 μM paclitaxel for 4 h, each including 0.43 μM[14C]carboplatin (106 dpm/ml). After washing, cells were maintained with 14C carboplatin-free culture media. DNA was extracted from cells and converted to graphite and measured by AMS for 14C quantification as previously described. |
Concentrations | 290 μM |
Incubation time | 4 h |
Animal Experiment | |
---|---|
Animal models | Female 6‐week‐old nude mice |
Formulation | |
Dosages | 100 mg/kg |
Administration | s.c. |
Molecular Weight | 371.25 |
Formula | C6H12N2O4Pt |
CAS Number | 41575-94-4 |
Solubility (25°C) | Water 4 mg/mL warmed |
Storage | 4°C, protect from light, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related DNA/RNA Synthesis Products |
---|
D-I03
D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 µM and 8 µM, respectively. |
Bractoppin
Bractoppin is a potent and selective inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain with IC50 of 74 nM. Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. |
Plitidepsin
Plitidepsin (Aplidine) is a potent anticancer compound targeting eEF1A2 (KD=80 nM). Plitidepsin has antiviral activity, and the IC90 of inhibiting SARS-CoV-2 is 0.88 nM. Plitidepsin is commonly used in multiple myeloma and advanced cancer research and has potential for COVID-19 research. |
Tofersen
Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce SOD1 protein synthesis. Tofersen can be used in amyotrophic lateral sclerosis (ALS) research. |
ART812
ART812 is an orally effective DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. ART812 had an IC50 value of 240 nM for cell-based microhomologous mediated end-junction (MMEJ). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.